



PROPOSED DOCUMENT

Global Harmonization Task Force

Title: Quality management system –Medical Devices – Guidance on corrective action and preventive action and related QMS processes

Authoring Group: Study Group 3

Date: 22nd September 2009

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

Table of Contents

Preface	3
Introduction.....	4
1.0 Scope	4
2.0 Definitions.....	5
2.1 Correction	5
2.2 Corrective action.....	5
2.3 Data Sources	5
2.4 Concession	5
2.5 Preventive action.....	5
2.6 Nonconformity	5
2.7 Verification	6
2.8 Validation.....	6
3.0 Overview	6
4.0 Phase I: Planning	8
4.1 Planning for Measurement, Analysis and Improvement Processes.....	9
4.2 Establish Data Sources and Criteria	10
5.0 Phase II: Measurement and Analysis within and across Data Sources.....	11
5.1 Measurement.....	11
5.2 Analysis	11
6.0 Phase III: Improvement	14
6.1 Investigate	15
6.2 Identify Root Cause	16
6.3 Identify Actions	17
6.4 Verification of identified actions	18
6.5 Implement Actions	19
6.6 Determine Effectiveness of Implemented Actions.....	19
7.0 Phase IV: Input to Management.....	19
7.1 Reporting to Management.....	19
7.2 Management Review.....	20
8.0 Annex A	21
9.0 Annex B	23
10.0 Annex C	24

69 Preface

70 The document herein was produced by the Global Harmonization Task Force, a voluntary group
71 of representatives from medical device regulatory agencies and the regulated industry. The
72 document is intended to provide non-binding guidance for use in the regulation of medical de-
73 vices, and has been subject to consultation throughout its development.

74
75 There are no restrictions on the reproduction, distribution or use of this document; however, in-
76 corporation of this document, in part or in whole, into any other document, or its translation into
77 languages other than English, does not convey or represent an endorsement of any kind by the
78 Global Harmonization Task Force.

79 Introduction

80 This guidance document is intended for medical device manufacturers and regulatory authorities.
81 It is intended for educational purposes and is not intended to be used to assess or audit compli-
82 ance with regulatory requirements. It is expected that the reader is familiar with regulatory Qual-
83 ity Management System (QMS) requirements within the medical devices sector.
84

85 For the purposes of this document it is assumed that the medical device manufacturer has a QMS
86 which requires the manufacturer to have documented processes to ensure that medical devices
87 placed on the market are safe and effective. For example ISO13485 Medical Devices – Quality
88 Management Systems – Requirements for regulatory purposes, Japanese Ministerial Ordinance
89 on Standards for Manufacturing Control and Quality Control for Medical Devices and in vitro
90 Diagnostics (MHLW¹ Ministerial Ordinance No. 169), and the FDA² Quality System Regulation
91 21 CFR Part 820.

92
93 For this purpose the manufacturer will establish processes and define appropriate controls for
94 measurement and analysis to identify nonconformities and potential nonconformities. The manu-
95 facturer should have established processes defining when and how corrections, corrective ac-
96 tions, or preventive actions should be undertaken. These actions should be commensurate with
97 the significance or risk of the nonconformity or potential nonconformity.
98

99 The acronym “CAPA” will not be used in this document because the concept of corrective action
100 and preventive action has been incorrectly interpreted to assume that a preventive action is re-
101 quired for every corrective action. This document will discuss the escalation process from differ-
102 ent “reactive” sources which will be corrective in nature and other “proactive” sources which
103 will be preventive in nature. The manufacturer is required to account for both types of data
104 sources whether they are of a corrective or preventive nature.
105

106 Regardless of the nature of the data source, if there is a decision to escalate the information to
107 further evaluation and investigation, the steps of investigation, identification of root causes and
108 actions needed, verification, implementation, and effectiveness checks will be similar.
109

110 This guidance document will describe measurement, analysis and improvement as complete and
111 integrated processes.
112

113 1.0 Scope

114 This document provides guidance for establishing adequate processes for measurement, analysis
115 and improvement within the QMS as related to correction and/or corrective action for noncon-
116 formities or preventive action for potential nonconformities of systems, processes or products.
117
118
119

¹ Japanese Ministry of Health Labor and Welfare

² US Food and drug Administration

120 **2.0 Definitions**

121 The references to clauses in this section refer to ISO 9000:2005.

122 **2.1 Correction**

123 Action to eliminate a detected nonconformity (3.6.2)

124 Note 1 A correction can be made in conjunction with corrective action (3.6.5)

125 Note 2 Corrections can be, for example, rework (3.6.7) or re-grade (3.6.8)

126

127 **2.2 Corrective action**

128 Action to eliminate the cause of a detected nonconformity (3.6.2) or other undesirable
129 situation

130 Note 1 There can be more than one cause for nonconformity

131 Note 2 Corrective action is taken to prevent recurrence whereas preventive ac-
132 tion (3.6.4) is taken to prevent occurrence

133 Note 3 There is a distinction between correction (3.6.6) and corrective action

134

135 **2.3 Data Sources**

136 The processes within a Quality Management System that provide quality information that
137 could be used to identify nonconformities, or potential nonconformities.

138

139 **2.4 Concession**

140 Permission to use or release a product that does not conform to specified requirements
141 (3.6.11).

142

143 **2.5 Preventive action**

144 Action to eliminate the cause of a potential nonconformity (3.6.2) or other undesirable
145 situation

146

147 Note 1 There can be more than one cause for nonconformity

148 Note 2 Preventive action is taken to prevent occurrence whereas corrective ac-
149 tion (3.6.5) is taken to prevent recurrence

150

151 **2.6 Nonconformity**

152 Non fulfillment of a requirement (3.1.2)

153

154 2.7 Verification

155 Confirmation through provision of objective evidence (3.8.1) that specified requirements
156 (3.1.2) have been fulfilled.

- 157
- 158 Note 1 The term “verified” is used to designate the corresponding status.
- 159 Note 2 Confirmation can comprise of activities such as:
- 160 - performing alternative calculations,
 - 161 - comparing a new design specification (3.7.3) with a similar proven
 - 162 design specification, undertaking tests (3.8.3), performing demonstra-
 - 163 tions, and reviewing and approving documents prior to issue.
 - 164

165 2.8 Validation

166 Confirmation through provision of objective evidence (3.8.1) that the requirements for a
167 specific intended use or application have been fulfilled.

- 168
- 169 Note 1 The term “validated” is used to designate the corresponding status.
- 170 Note 2 The use conditions for validation can be real or simulated.
- 171

172 3.0 Overview

173 The Management of any medical device manufacturer is ultimately responsible for establishing
174 adequate processes for measurement, analysis and improvement within the QMS as related to
175 correction and/or corrective action (action to prevent the recurrence) of nonconformities or pre-
176 ventive action (action to prevent the occurrence) of potential nonconformities of product or proc-
177 esses.

178

179 A nonconformity as defined in 2.6 is a non fulfillment of a requirement. It is important to under-
180 stand that requirements may relate to product, process or the QMS.

181

182 When a nonconformity is identified, the manufacturer will determine the significance, risk of the
183 nonconformity and the potential for recurrence. Once these have been determined the manufac-
184 turer may decide the nonconformity has little associated risk or is unlikely to recur. In such cases
185 the manufacturer may decide only to carry out a correction.

186

187 Should the nonconformity recur within the QMS, during manufacture or after the medical device
188 has been delivered to a customer, it is an indication that improvement action is needed. In either
189 case the QMS requires that corrective action should be carried out with the aim to prevent recur-
190 rence. The corrective action may be as simple as retraining, or as complex as redesigning the
191 manufacturing process.

192

193 The manufacturer may encounter situations that have not actually caused a nonconformity, but
194 may do so in the future. Such situations may call for preventive action. Examples include:

195

- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- Corrective actions are taken within a QMS to eliminate observed nonconformities (regardless of whether the actions are taken for more than one site or facility operating within that QMS). Similar actions applied in another QMS (regardless whether it is the same or a different manufacturer) that has not yet experienced these nonconformities, would be considered preventive actions.
 - Production or acceptance testing trend data indicates that control limits are being approached and revision of product or production (process, equipment or facilities) requirements may be necessary. These revisions could constitute a preventive action. Preventive action would not include planned process adjustments intended to return process performance to nominal values from the edges of the process control range.

207 Figure 1 illustrates typical Phases to be considered when planning, implementing and maintain-
208 ing effective processes for measurement, analysis, improvement and providing input to manage-
209 ment.

210

211 The Management should ensure that measurement criteria are defined for identified data sources
212 and communicated across the organization.

213


214 As a check on the effectiveness of the processes defined, management should regularly review
215 the outputs of processes and make adjustments as needed.

216

217 Documented procedures, requirements and records should be maintained by the manufacturer to
218 ensure and demonstrate the effective planning, operation and control of the processes. Docu-
219 mented evidence of decisions and actions taken will be a part of the QMS.

220

221



222
223
224
225

Figure 1: Processes for measurement, analysis and improvement

226 **4.0 Phase I: Planning**

227 The manufacturer is responsible for the implementation and maintenance of a QMS which en-
228 ables their organization to provide safe and effective medical devices meeting customer and
229 regulatory requirements.

230
231 Implementing and maintaining an effective QMS is a responsibility of top management in an or-
232 ganization. The involvement of management at appropriate levels of the organization (e.g. re-
233 view, approval) in actions taken in response to a nonconformity or potential nonconformity
234 should be established.

235
236 Risk Management activities are to include risk control and risk mitigation outputs should be con-
237 sidered throughout planning.

238
239
240

241 **4.1 Planning for Measurement, Analysis and Improvement Processes**

242 Factors to consider during this planning phase should be aligned with the manufacturer's overall
243 business planning and as a minimum include the type of device being manufactured, intended
244 markets and users, and regulatory requirements. As part of planning, management should review
245 the processes critical to the operations with regard to quality and regulatory requirements and
246 select relevant data sources to measure, analyze and facilitate improvement as necessary.

247
248 In the process of planning, measurement and analysis, a manufacturer needs to take into account
249 data sources, the measurement of the data elements within each data source, the frequency of
250 monitoring, and the analysis to be performed within a data source, or across data sources.

251
252 The measurement of data elements should be done in a way that ensures the organization will be
253 effective in managing the operations and having an effective QMS. Each of the data elements
254 should be planned and established with specific requirements for measurement that are moni-
255 tored routinely.

256
257 The scope of the QMS and the scope of the measurement, analysis and improvement processes
258 will provide the boundaries as to whether the data source is reactive/corrective or proac-
259 tive/preventive.

260
261 The planning phase should ensure the following:

- 262
263 1. Identification of relevant internal and external data sources that are indicators of process
264 and product performance.
- 265
266 2. Provision for adequate resources and establish responsibilities and authorities to enable
267 the necessary actions. Resources may include technical experts, testing laboratories, data
268 management, infrastructure, training, etc.
- 269
270 3. Definition of requirements for each identified data source, including limits, acceptance
271 criteria, escalation criteria and mechanisms for reporting of nonconformities or potential
272 nonconformities.
- 273
274 4. Analysis of data elements within data sources.
- 275
276 5. Coordination and analysis of data across data sources.

277
278 For each data element individual criteria should be defined, however criteria may be defined for
279 a combination of data elements. Criteria should be quantitative whenever possible in order to
280 maximize consistency and reproducibility for subsequent analysis. If the criteria and data are
281 qualitative, subjectivity should be eliminated or minimized.

282
283 Acceptance criteria should be based on system, product and process specifications or require-
284 ments which are typically identified during design and development activities. This includes the
285 design of the Quality Management System, development and maintenance of assembly proc-
286 esses, delivery processes, servicing and installation processes.

287
288 Escalation criteria used for the purpose of initiating the improvement process (see 6.0 Phase III:
289 Improvement) may often be called action levels, trigger points, thresholds, etc. In particular, cri-
290 teria should be established for immediate escalation. These criteria would be identified from risk
291 management activities. For new technology and existing technologies with new intended
292 uses/applications, initial escalation criteria may be difficult to define for the monitoring process.
293 Therefore a manufacturer should plan for resources to analyze information in order to confirm
294 initial assumptions and establish or revise escalation criteria.

295
296 Planning should provide for confirmation that the defined limits, acceptance criteria, escalation
297 criteria and mechanisms for reporting of nonconformities or potential nonconformities for the
298 original data sources and data elements are still appropriate. Where new data sources need to be
299 established, confirm that they have been identified and their criteria defined.
300

301 **4.2 Establish Data Sources and Criteria**

302 The manufacturer should identify and document relevant data sources and their data elements,
303 both internal and external to the organization. Data elements provide information regarding non-
304 conformities, potential nonconformities and the effectiveness of the established processes within
305 the data sources. Consideration should be given to the management review data and regulatory
306 requirements.

307
308 Examples of data sources can be, but are not restricted to:

- 309
- 310 ▪ Supplier
 - 311 ▪ Performance/Controls
 - 312 ▪ Complaint Handling
 - 313 ▪ Adverse Event Reporting
 - 314 ▪ Process Controls
 - 315 ▪ Finished Product
 - 316 ▪ Quality Audits (internal/external)
 - 317 ▪ Product Recall
 - 318 ▪ Spare Parts Usage
 - 319 ▪ Service Reports
 - 320 ▪ Returned Product
 - 321 ▪ Market/Customer Surveys
 - 322 ▪ Literature
 - 323 ▪ Management Review
 - 324 ▪ Product Realization (Design, Purchasing, Production and Service and Customer informa-
325 tion)

326
327 For further examples of data elements see Annex A.

328
329 When action taken is limited to the specific area where the data has come from, correction of a
330 significant situation may be delayed. It is important that the manufacturer reviews the informa-
331 tion that is being identified across the organization. When the information is reviewed across

332 data sources it is clear what needs to be done. A manufacturer should look for common factors
333 across the data sources. Doing so will lead to an effective corrective action.
334

335 **5.0 Phase II: Measurement and Analysis within and across Data Sources**

336 Once data sources, data elements and acceptance criteria have been specified, as part of the plan-
337 ning process, the manufacturer is required to perform measurement, monitoring and analysis
338 processes to determine conformity or nonconformity.
339

340 Software used in measurement, monitoring and analysis, whether purchased (Off-The-Shelf) or
341 custom developed, should be validated for its intended use.
342

343 **5.1 Measurement**

344 For the purposes of guidance, measurement is a set of operations to determine a value of a data
345 element (i.e. quantity, quality).
346

347 Data collected from the measurement of product, process and QMS are acquired throughout the
348 life-cycle of the product. The manufacturer should define for example frequency of the meas-
349 urement, precision and accuracy of the data. The manufacturer should also ensure that the data
350 collected is current and relevant.
351

352 Measurement data should be retained as a quality record. The manufacturer should maintain the
353 data in a form that is retrievable, suitable for analysis and meets both QMS and regulatory re-
354 quirements.
355

356 Monitoring is the systematic and regular collection of a measurement. The manufacturer should
357 define during the planning phase what, when and how data should be monitored. The data should
358 be defined such that it can be analyzed for further action. The monitoring of data may be con-
359 tinuous or periodic, depending on the type of data source and elements. The monitoring proc-
360 esses should be periodically reviewed for their continued suitability.
361

362 **5.2 Analysis**

363 For the purpose of this guidance Analysis is a systematic review and evaluation of data from
364 measurements to derive a conclusion.
365

366 The manufacturer should have documented procedures for the analysis of data against the estab-
367 lished criteria. Analysis is performed to identify nonconformity or potential nonconformity or
368 identify areas where further investigation should be initiated (see 5.2 Analysis). In addition
369 analysis is used to demonstrate the suitability and effectiveness of product, process and QMS.
370 Analysis can be performed utilizing analytical tools, a team of experts, process owners or inde-
371 pendent reviewers. The results of the analysis should be documented.
372

373 After it is determined what will be measured, statistical techniques used should be identified to
374 help understand variability and thereby help the manufacturer to maintain or improve effective-
375 ness and efficiency. These techniques also facilitate better use of available data to assist in deci-
376 sion making. Statistical techniques assist in identifying, measuring, analyzing, interpreting and
377 modeling variability.

378

379 For the analysis of nonconformity, appropriate statistical and non-statistical techniques can be
380 applied. Statistical techniques are for example:

- 381 ▪ Statistical Process Control (SPC) charts
- 382 ▪ Pareto analysis
- 383 ▪ Data trending
- 384 ▪ Linear and non-linear regression analysis
- 385 ▪ Experimental design (DOE – Design of Experiments) and analysis of variance
- 386 ▪ Graphical methods (histograms, scatter plots, etc.)

387

388 Non-statistical techniques are for example:

- 389 ▪ Management reviews
- 390 ▪ Results from quality meetings
- 391 ▪ Safety committees (internal or external)
- 392 ▪ Failure Mode and Effect Analysis (FMEA)
- 393 ▪ Fault Tree Analysis (FTA)

394

395 Analysis will likely occur at several different points (time and/or organizational level). For ex-
396 ample, a certain amount of analysis and possible failure investigation (where there is evidence of
397 a nonconformity) will occur for each data source.

398

399 In addition to the analysis within the data sources there should also be a level of analysis across
400 data sources to determine the extent and significance of nonconformity or potential nonconform-
401 ity. The linkage of data from different data sources will be referred to as “horizontal analysis”.

402 The horizontal analysis may:

403

- 404 1. determine that the action proposed from the data source analysis is appropriate without
405 further progress into Phase III (see 6.0); or,
- 406 2. provide additional information warranting progress into Phase III (see 6.0), regardless of
407 whether the data source analysis escalated the nonconformity or potential nonconform-
408 ity.

409

410 For example, the data source market/customer survey may indicate a general dissatisfaction with
411 the performance of a kind of product. When investigated further and reviewed with other data
412 sources such as complaints, returned product and if applicable, service reports, a significant non-
413 conformity becomes evident in the product or family of products and for which corrective action
414 is required. Thus, the necessary escalation to Phase III (see 6.0) for corrective action occurs. In-
415 tegral to this escalation is the determination of the Scope of the investigation, including the de-
416 termination of whether the nonconformity arises from a systemic issue.

417




Figure 2: Outcomes of measurement and analysis

The outcome of the analysis would lead to one of the following decisions (see Figure 2):

- 418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
- A. No correction required, continue measurement and monitoring.
The decision is made not to take any correction nor escalate the handling of the nonconformity to Phase III (see 6.0). **No Correction** **A**
 - B. Correction required, continue measurement and monitoring
The decision is made to perform a correction but not to escalate the handling of the nonconformity to Phase III (see 6.0). **analyze**
 - C. Correction and escalation to further investigation under the improvement process.
The decision is made to perform a correction and to escalate the handling of the nonconformity to Phase III (see 6.0). **monitor**
 - D. Escalation for further investigation under the improvement process because there is not enough information at this time to determine the required action. In addition there may be predefined events that due to the significance of the risk will automatically be escalated to Phase III without an immediate correction. **measure**

440 In the event a potential nonconformity is identified, it may be escalated into Phase III (see
441 6.0) for consideration of actions to prevent the occurrence of the potential nonconformity.
442

443 For Options A, B and C, both the data source analysis and the horizontal analysis, continue to
444 occur on a monitoring basis to ensure risk and frequency assumptions remain valid.
445

446 For Options A and B the activities described in Phase III can be accomplished within certain
447 processes (e.g. Change Management Process) if it is predefined and described in documented
448 procedures. In addition there needs to be a process monitoring or analysis (i.e. trending) of the
449 corrective actions to determine if additional escalation is necessary. Otherwise the activities in
450 Phase III will be escalated as part of the improvement process.
451

452 When a nonconformity or potential nonconformity is escalated into Phase III (see 6.0), the non-
453 conformity or potential nonconformity will undergo additional analysis and possible investiga-
454 tion.
455

456 Typically manufacturers have functional groups or processes surrounding some of their main
457 data sources (e.g. Complaint Handling, handling of nonconformities, Material Review Boards,
458 Change Management Process). Within these functional groups or processes certain activities
459 described in Phase III (see 6.0 Phase III: Improvement) can implement immediate corrections.

460 These immediate corrections, or the decision to not implement an immediate correction, (de-
 461 scribed in Figure 2 - Options A, B and C) can occur without or before the escalation to Phase III
 462 as long as the functional groups or processes, and their documented procedures, clearly delineate
 463 and define the activities that can be accomplished without or before escalation to Phase III.
 464

465 As discussed above, when no correction or immediate correction are taken within these func-
 466 tional groups or processes, there needs to be data source monitoring and analysis (trending) to
 467 determine if escalation to Phase III may be necessary from accumulated information. Whenever
 468 an issue is escalated to Phase III, any information gained within the defined activities of these
 469 functional groups or processes should be fed into the Phase III activities such as Investigation
 470 (see 6.1) or Identified Actions (see 6.3)
 471

472 **6.0 Phase III: Improvement**


473 The improvement phase of a corrective action process or preventive action process is designed to
 474 eliminate or mitigate a nonconformity or potential nonconformity.
 475

476 The improvement activities are tailored to the specific nonconformity or potential nonconform-
 477 ity. The amount of work in Phase III is therefore dependant upon the risk and significance of the
 478 nonconformity or potential nonconformity.
 479

480 The improvement process and the activities described in Figure 3 shall be documented. Im-
 481 provement generally involves the following activities that the manufacturer would take sequen-
 482 tially or sometimes simultaneously:
 483

- 484 ▪ A thorough investigation of the reported nonconformity;
- 485 ▪ An in-depth root cause analysis;
- 486 ▪ Identification of appropriate actions;
- 487 ▪ Verification of identified actions;
- 488 ▪ Implementation of actions; and
- 489 ▪ Effectiveness check of implemented actions.

490
 491



492
 493
 494

Figure 3: Phase III - Improvement

495 6.1 Investigate

496 The investigation documentation should include a statement of the nonconformity expressed as a
497 problem statement. In addition the documentation should include the extent of the nonconformity
498 or potential nonconformity, the conduct of the investigation, the method, resources, timeframe
499 and records to be used and generated. From the information obtained throughout the process the
500 problem statement should be reviewed and refined as appropriate.

501
502 The conduct of the investigation should:

- 503 ▪ Determine the extent of the nonconformity or potential nonconformity;
- 504 ▪ Acknowledge that there is likely to be several causes of an event, hence the investigation
505 should not cease prematurely;
- 506 ▪ Require that symptoms be distinguished from root causes and advocate the treatment of
507 root causes rather than just the symptoms;
- 508 ▪ Require that an end point be defined for the investigation. (An exhaustive investigation
509 may unduly delay the correction of non-conformity or unnecessarily incur additional cost.
510 For example; if removal of the causes identified so far will correct 80% of the effects
511 then it is likely that the significant causes have been identified (Pareto rule))
- 512 ▪ Take into account the output of relevant risk management activities;
- 513 ▪ Agree on the form of evidence. For example, evidence should support:
 - 514 - the seriousness of the event;
 - 515 - the likelihood of occurrence of the event;
 - 516 - the significance of the consequences flowing from the event;

517
518 A recognized method for the investigation should include the collection of data and the organiza-
519 tion of that data to allow analysis. The majority of time spent analyzing an event is spent in gath-
520 ering data.

521
522 The investigation should build upon any analysis, evaluation and investigation that were previ-
523 ously performed (see 5.0). This will require the investigator to identify, define and further docu-
524 ment the observed effects / non-conformity, or already determined causes, to ensure that the in-
525 vestigator understands the context and extent of the investigation. It may be necessary to:

- 526 ▪ Review and clarify the information provided;
- 527 ▪ Review any additional information available from an horizontal analysis;
- 528 ▪ Consider whether this is a systemic issue/non-systemic issue.
- 529 ▪ Gather additional evidence, if required;
- 530 ▪ Interview process owners / operators or other parties involved;
- 531 ▪ Review documents;
- 532 ▪ Inspect facilities, or the environment of the event;

533
534 Previous investigations should be reviewed in order to determine if the event is a new problem or
535 perhaps the recurrence of a previous problem where, for example, an ineffective solution was
536 implemented. The following questions will assist in making the determination:

- 537 ▪ Is the nonconformity from a single data source?
- 538 ▪ Does the current nonconformity correlate with nonconformities from other data sources?
- 539 ▪ Are multiple data sources identifying the same nonconformity?
- 540 ▪ Do other nonconformities have an effect on the problem investigated here?

541 The systematic recording of observations, and the relationship between observations, will sup-
542 port a cause and effect analysis, and will assist to identify gaps in an understanding of the non-
543 conformity.

544

545 Many of the tools used in investigations rely upon a cause and effect relationship between an
546 event and a symptom of that event. To ensure that causes are identified, not symptoms, the fol-
547 lowing should be considered:

- 548 ▪ There must be a clear description of a cause and its effect. The link between the root
549 cause and the undesirable outcome needs to be described.
- 550 ▪ Each description of a cause must also describe the combined conditions that contribute to
551 the undesired effect.
- 552 ▪ Each deviation from a procedure should have a reason. Therefore the reason for the de-
553 viation (root cause) should be identified, not just the symptom (occurrence of a devia-
554 tion).
- 555 ▪ A failure to act is only considered a cause if there was a pre-existing requirement to act.
556 The requirement to act may arise from a procedure, or may also arise from regulations,
557 standards or guidelines for practice, or other reasonably expected actions.

558

559 Some of the more common tools and techniques include:

- 560 ▪ Cause and effect diagrams
- 561 ▪ 5 whys
- 562 ▪ Pareto Charting
- 563 ▪ Fishbone cause and effect diagrams
- 564 ▪ Change analysis
- 565 ▪ Risk analysis techniques

566

567 The outcome of an investigation should include:

- 568 ▪ Clearly defined problem statement
- 569 ▪ What information was gathered, reviewed and/or evaluated
- 570 ▪ Results of the reviews/evaluations of the information
- 571 ▪ Identification of possible root causes of the nonconformity or potential nonconformity
- 572 ▪ Possible solutions to address the causes

573

574 **6.2 Identify Root Cause**

575 Causes of detected nonconformity or potential nonconformity should promptly be identified so
576 that corrective action can be taken to prevent recurrence, or preventive action taken to prevent
577 occurrence. The process to identify the root cause should start with the output(s) of the investiga-
578 tion (see 6.1).

579

580 When assessing relevant data, the following should be considered:

581

- 582 ▪ Systematic generation of cause and effect conclusions supported by documented evidence
- 583 ▪ Evaluate significant or underlying causes and their relationship to the problem
- 584 ▪ Ensure that all causes are identified, not the symptoms
- 585 ▪ Check for more than one root cause (above processes if necessary)

586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605

Causes of nonconformities or potential nonconformities may include the following:

- Failure of, or malfunction of, incoming materials, processes, tools, equipment or facilities in which products are processed, stored or handled, including the equipment and systems therein;
- inadequate or non-existent procedures and documentation;
- non-compliance with procedures;
- inadequate process control;
- inadequate scheduling;
- lack of training;
- inadequate working conditions;
- inadequate resources (human or material);
- (inherent) process variability.

For further details on aspects to be considered when doing the root cause analysis see Annex B.

The output of the root cause analysis should be a clear statement of the cause(s) of the nonconformity.

606 **6.3 Identify Actions**

607 Once the root cause(s) has been determined, the manufacturer should identify and document the
608 necessary corrections and/or corrective actions or preventive actions. These should be reviewed
609 to ensure that all necessary actions are identified. This review may benefit from a cross func-
610 tional approach.

611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630

The following outcomes are possible and should be documented:

1. No further action necessary.
(provided that no safety issue exists and regulatory requirements are met)
 - a. With continuous monitoring
 - b. Acceptance under concession and continuance of monitoring
2. Corrections or additional corrections.
It may be necessary to take immediate or short term corrections (e.g. containment, stop of shipment/supply, issuance of advisory notice) in order to address an immediate risk or safety issue. This may be necessary before investigation has been completed and root cause has been determined. However, after investigation and root cause determination, additional and/or possibly different corrections may become necessary.
3. Corrective Actions
Corrective actions must encompass the need to correct the nonconformity and in addition address systemic problems. Changing and training of personnel to a new procedure may not, by itself, be appropriate or sufficient to address all identified root causes.

631 4. Preventive action

632 By its very nature preventive action can not follow a nonconformity.

633

634 As a result of this step, a list of action items to address the root cause(s) should be documented.

635 These would typically include:

636

637 ■ Detail method of implementation;

638 ■ Applicable regulatory requirements;

639 ■ Identification of the responsibilities during execution;

640 ■ Identification of the necessary resources, including the human resources;

641 ■ Verification and/or validation protocols of the action(s) with acceptance criteria;

642 ■ Implementation schedule, including timelines.

643 ■ Method or data for the determination of effectiveness

644 ■ Identify the starting point of monitoring, and end point of correction and/or corrective ac-
645 tion or preventive action as described above

646

647 **6.4 Verification of identified actions**

648 Before the implementation of action(s), a manufacturer should verify the identified action(s) and
649 approve their implementation. In addition validation may be required where process validation or
650 re-validation may be necessary, or where user needs or intended uses are changed and design
651 validation will be required. The decision as to the necessity for validation is influenced, among
652 other things, by the risk associated with the nonconformity, the complexity of the corrective or
653 preventive action, and the costs associated with the implementation of the corrective or preven-
654 tive action.

655

656 Verification activities are to ensure that all the elements of the proposed action (documentation,
657 training etc) will satisfy the requirements of the proposed action (see 2.7). These activities should
658 be performed by persons who are knowledgeable in the design or use of the product or process
659 that is the subject of corrective or preventive action. Verification of a preventive action can be
660 accomplished by introducing the conditions that would induce a nonconformity and confirming
661 that the nonconformity does not occur.

662

663 Validation activities generate data and information that confirm the likelihood of the effective-
664 ness of the corrective action to eliminate the nonconformity or proposed nonconformity.

665

666 Examples of items to be considered when planning the verification / validation activities include:

667

668 ■ Does the action(s) eliminate the determined root cause(s)?

669 ■ Does the action(s) cover all affected products/processes?

670 ■ Does the action(s) adversely affect the final products?

671 ■ Is it possible to finalize the actions timely in planned schedule
672 (resources, materials/kits, logistics, communications, etc.)?

673 ■ Is the execution of the action commensurate with the degree
674 of risk previously established?

675 ■ Are new risks or nonconformities derived from the action?

676

677 **6.5 Implement Actions**

678

679 The following items that may be considered at implementation should be documented:

- 680 ▪ parties involved,
- 681 ▪ materials,
- 682 ▪ processes,
- 683 ▪ training,
- 684 ▪ communications,
- 685 ▪ tools and
- 686 ▪ timelines for the implementation of the approved action.

687

688 Verify that the implementation has been completed.

689

690 **6.6 Determine Effectiveness of Implemented Actions**

691 The manufacturer should gather data over a period of time related to the effectiveness of the im-
692 plemented action. The manufacturer confirms that actions taken were effective as to the intended
693 purpose of the action and did not introduce new issues or concerns.

694

695 If the manufacturer finds the actions are not effective, the manufacturer should re-initiate Phase
696 III activities (see 6.0). If the manufacturer finds the actions create a new issue or a new noncon-
697 formity then the manufacturer needs to initiate Phase II (see 5.0) activities.

698

699 **7.0 Phase IV: Input to Management**

700 Management at different levels in the organization should be involved in each improvement ac-
701 tion either through approval of the improvement steps or reporting. The Management Review is
702 the overall mechanism for management to ensure that the Quality Management System as a
703 whole is effective.

704

705 **7.1 Reporting to Management**

706 The manufacturer should have a mechanism/procedure that expeditiously raises safety related
707 issues or other high risk issues to management. These issues can be identified in the data sources,
708 the improvement process (see 6.0), or originate from other sources external to the Quality Man-
709 agement System. In addition to this expeditious escalation mechanism, the manufacturer should
710 define the management responsibilities (i.e. process owner) of the measurement, analysis and
711 improvement processes to ensure that the processes and the actions being implemented are effec-
712 tive. For this purpose there needs to be a mechanism for management at different levels to stay
713 informed of the information or data from:

714

- 715 ▪ the measurement and analysis activities from the individual data sources; and
- 716 ▪ the investigations, actions, implementations, etc. from the improvement process

717

718 7.2 Management Review

719 The manufacturer has procedures for what is provided as input for the management review, in-
720 cluding relevant information from the improvement process, such as improvement actions (cor-
721 rective actions, or preventive actions) as well as important corrections.

722

723 The manufacturer needs to define what meaningful data is to be reported for a management re-
724 view. Data should be specific to the quality objectives of the manufacturer and be reported regu-
725 larly. Merely providing the number of improvement actions or the number of how many im-
726 provement actions are opened or closed to the management review process are not sufficient in
727 assessing the effectiveness of the processes.

728

729 Included in this review would be an assessment of any opportunities for improvement of the de-
730 vice, manufacturing process, QMS or the organization itself.

731

732 An outcome of the review could be the allocation of funding or personnel to a particular area,
733 project or device that the review has identified as not meeting customer and regulatory safety and
734 effectiveness expectations.

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759 **8.0 Annex A**

760 Examples of data sources and their data elements can be, but are not restricted to:

761

762

DATA SOURCES	DATA ELEMENTS
Supplier Performance/Controls	<ul style="list-style-type: none"> ▪ Number of batches received ▪ Batch and/or shipment ▪ Inspection and test records ▪ Quantity of rejects or deviations ▪ Reason for rejection ▪ By supplier, if more than one supplier ▪ Use in which product or service ▪ Supplier problems
Complaint Handling	<ul style="list-style-type: none"> ▪ Quantity ▪ By product family ▪ By customer (physician, healthcare facility, patient, etc.) ▪ Reason for complaint ▪ Complaint codes ▪ Severity ▪ Component involved
Adverse Event Reporting	<ul style="list-style-type: none"> ▪ Event ▪ Quantity ▪ By product family ▪ By customer (physician, healthcare facility, patient, etc.) ▪ Type of event (death or serious injury, etc.) ▪ Component involved
Process Controls	<ul style="list-style-type: none"> ▪ By product ▪ Operator ▪ Work shift ▪ Equipment and/or instruments used ▪ Inspection and test records ▪ In-process control results ▪ Process control parameters ▪ Inspection process ▪ Final acceptance ▪ Rejects ▪ Special process ▪ Validation study results ▪ Process monitoring observations
Finished Product	<ul style="list-style-type: none"> ▪ Inspection and test records
Quality Audits (internal/external)	<ul style="list-style-type: none"> ▪ Observations (number, category, corporate policy, regulatory requirements, significance, etc.) ▪ Repeat observations (indicative of effectiveness) ▪ Closure times ▪ Overall acceptability of contractor or supplier ▪ Compliance to audit schedule ▪ Audit personnel
Product Recall	<ul style="list-style-type: none"> ▪ Recall report

DATA SOURCES	DATA ELEMENTS
Spare Parts Usage	<ul style="list-style-type: none"> ▪ Frequency of replacement ▪ Batch number of spare part ▪ By supplier of spare part, if more than one supplier ▪ By customer ▪ By location or area of customer
Service Reports	<ul style="list-style-type: none"> ▪ Installation ▪ First use of equipment ▪ Frequency of maintenance visits ▪ Types of repairs ▪ Frequency of repairs ▪ Usage frequency ▪ Parts replaced ▪ Service personnel
Returned Product	<ul style="list-style-type: none"> ▪ Quantity ▪ Reason for returning product ▪ By customer ▪ Types of defects identified on returned product
Market/Customer Surveys	<ul style="list-style-type: none"> ▪ Customer preferences ▪ Customer service response time ▪ Solicited information on new or modified products
Literature	<ul style="list-style-type: none"> ▪ Published reports of failures of similar products
Management Review	<ul style="list-style-type: none"> ▪ Management review output
Product Realization (Design, Purchasing, Production and Service and Customer information)	<ul style="list-style-type: none"> ▪ Design and development review results ▪ Verification of design and development to ensure output meets input requirements ▪ Validation results ▪ Design and development changes (reason or cause for change) ▪ Where changes effective ▪ Note; each of the above has specific data that is generated from performing the activities as a result the data should be monitored and results reviewed on a regular basis to ensure the processes and the product are effective. ▪ Purchasing- Supplier controls ▪ Controls on purchased products or services (See above Supplier Performance/Controls) ▪ Verification results of purchased product ▪ Inspection and testing data of purchased product ▪ Production and Service processes- Cleaning operations of product and facilities ▪ Sterilization ▪ Installation results ▪ Servicing and Maintenance if required (See also: Service Reports) ▪ Verification and Validation results of processes used in production and service. Including approval of equipment and qualification of personnel ▪ Traceability Data ▪ Controls of monitoring and measuring devices ▪ Calibration and maintenance of equipment ▪ Customer Information- New or repeat customer ▪ Customer feedback maybe in other forms than complaints or returned product (Customer Service call data, repeat sales , delivery/distribution data)

763

764 **9.0 Annex B**

765 Checklist for aspects to be considered when doing the root cause analysis:

766

767 Materials

- 768 ▪ Defective raw material (does material meet specification?)
- 769 ▪ Batch related problem
- 770 ▪ Design problem (wrong material for product, wrong specifications)
- 771 ▪ Supplier problem (lack of control at supplier, alternative supplier)
- 772 ▪ Lack of raw material.

773

774 Machine / Equipment

- 775 ▪ Incorrect tool selection – suitability
- 776 ▪ Inadequate maintenance or design – calibration?
- 777 ▪ Equipment used as intended by the manufacturer?
- 778 ▪ Defective equipment or tool
- 779 ▪ End of life?
- 780 ▪ Human error – inadequate training?

781

782 Environment

- 783 ▪ Orderly workplace
- 784 ▪ Properly controlled – temperature, pressure, particulate, cleanliness
- 785 ▪ Job design / layout of work

786

787 Management

- 788 ▪ Inadequate management involvement
- 789 ▪ Stress demands
- 790 ▪ Human factors
- 791 ▪ Hazards not properly guarded
- 792 ▪ Were management informed / did they take action?

793

794 Methods

- 795 ▪ Procedures not adequately defined
- 796 ▪ Practice does not follow written method
- 797 ▪ Poor communications

798

799 Management system

- 800 ▪ Training or education lacking
- 801 ▪ Poor employee involvement
- 802 ▪ Poor recognition of hazard
- 803 ▪ Previous hazards not eliminated

804

805 Measurement, monitoring and improvement

- 806 ▪ Inadequate measuring and improvement

807

808

809 **10.0 Annex C**

810 List of Activities corresponding to phases in the processes

811

812 The following is an outline / aid memoir of the main points described in SG3 N18. It is not in-
 813 tended as a “box ticking” exercise and should not be used as such, but used purely to summarise
 814 and align the steps in the process described in N18. The activity numbers do not imply sequential
 815 steps – some steps may take place in parallel.

816

817 Steps 20 to 22 are not described in N18 but are added as reminders of general management re-
 818 sponsibilities in this area of the QMS.

819

PHASE

1 Planning

ACTIVITIES

1. Identify all data sources (internal & external) by product type (Clause 4.1)
2. Identify resources required and individual personnel responsibilities for measuring each data source (Clause 4.1)
3. Define the requirements for each data source and the data elements within each data source that will be measured, and analysed (Clause 4,1)
4. Define requirements for escalation to the Improvement process (Clause 4,1)
5. Define requirements for monitoring the measurements in the data sources (Clause 5.1)
6. Establish data sources (Clause 4.2)

2 Measuring and Analysis

7. Measure and analyse all data sources for nonconformities and potential nonconformities (Clauses 5.0, 5.1 and 5.2)
8. Have reports of nonconformity or potential nonconformity come from more than one data source?
9. Is the nonconformity or potential nonconformity systemic?

3 Improvement

10. Determine scope and required outcome of investigation (Clause 6.1)
11. Investigate nonconformity or potential nonconformity (Clause 6.1)
12. Analyse nonconformity or potential nonconformity for root cause(s) (Clause 6.2)
13. Identify actions (correction, corrective

PHASE**ACTIVITIES**

4 Management

- action or preventive action) (Clause 6.3)
14. Verify proposed actions before implementation (Clause 6.4)
 15. Implement proposed actions (Clause 6.5)
 16. Determine effectiveness of actions (validate if possible) (Clause 6.6)
 17. Report investigation and outcome to management (Clause 7.1)
 18. Review investigation, analysis and outcome and sign off (Clause 7.2)
 19. If not satisfied return to step 10
 20. If required, report to regulator (note: reporting may be required earlier depending on severity)
 21. Audit system at determined intervals
 22. If numbers of nonconformities or potential nonconformities exceeds targets, review all QMS processes